MA52742A - Anticorps bispécifiques dll3-cd3 - Google Patents

Anticorps bispécifiques dll3-cd3

Info

Publication number
MA52742A
MA52742A MA052742A MA52742A MA52742A MA 52742 A MA52742 A MA 52742A MA 052742 A MA052742 A MA 052742A MA 52742 A MA52742 A MA 52742A MA 52742 A MA52742 A MA 52742A
Authority
MA
Morocco
Prior art keywords
dll3
bispecific antibodies
bispecific
antibodies
antibodies dll3
Prior art date
Application number
MA052742A
Other languages
English (en)
Inventor
Paul Adam
Michael Dziegelewski
Rajkumar Ganesan
Philip Nicholas Gorman
Pankaj Gupta
Priyanka Gupta
Susanne Hipp
Justin Scheer
Vladimir H Voynov
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA52742A publication Critical patent/MA52742A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
MA052742A 2018-06-09 2019-06-07 Anticorps bispécifiques dll3-cd3 MA52742A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18176888 2018-06-09
EP18176889 2018-06-09
EP19159321 2019-02-26

Publications (1)

Publication Number Publication Date
MA52742A true MA52742A (fr) 2021-04-14

Family

ID=66752128

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052742A MA52742A (fr) 2018-06-09 2019-06-07 Anticorps bispécifiques dll3-cd3

Country Status (21)

Country Link
US (3) US11332541B2 (fr)
EP (1) EP3802598A1 (fr)
JP (2) JP7133043B2 (fr)
KR (1) KR20210018311A (fr)
CN (1) CN112513092A (fr)
AU (1) AU2019280900A1 (fr)
BR (1) BR112020022898A2 (fr)
CA (1) CA3099956A1 (fr)
CL (1) CL2020003105A1 (fr)
CO (1) CO2020015172A2 (fr)
CR (1) CR20200601A (fr)
EC (1) ECSP20084864A (fr)
IL (1) IL279235A (fr)
JO (1) JOP20200313A1 (fr)
MA (1) MA52742A (fr)
MX (1) MX2020013348A (fr)
PE (1) PE20210321A1 (fr)
PH (1) PH12020552080A1 (fr)
SG (1) SG11202011134XA (fr)
TW (1) TW202016151A (fr)
WO (1) WO2019234220A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3732195A4 (fr) * 2017-12-28 2022-02-09 Chugai Seiyaku Kabushiki Kaisha Agent thérapeutique induisant une cytotoxicité
TW202128756A (zh) * 2019-10-02 2021-08-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
US11976133B2 (en) * 2020-01-31 2024-05-07 Gensun Biopharma Inc. Bispecific T cell engagers
AU2021276332A1 (en) 2020-05-19 2022-11-17 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
US20240002476A1 (en) * 2020-05-20 2024-01-04 The Trustees Of Columbia University In The City Of New York Potent neutralizing antibodies against sars-cov-2, generation and uses thereof
CN111551733A (zh) * 2020-05-29 2020-08-18 武汉大学 定量检测免疫细胞来源细胞外囊泡pd-1含量的方法、elisa试剂盒及使用方法
EP4214233A1 (fr) 2020-09-16 2023-07-26 Amgen Inc. Méthodes d'administration de doses thérapeutiques de molécules bispécifiques activant les lymphocytes t pour le traitement du cancer
WO2022153194A1 (fr) * 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Conjugué anticorps-dérivé de pyrrolobenzodiazépine
TW202245844A (zh) * 2021-01-13 2022-12-01 紀念斯隆凱特琳癌症中心 抗dll3抗體-藥物結合物
US20220388986A1 (en) 2021-04-29 2022-12-08 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
WO2023031409A1 (fr) 2021-09-02 2023-03-09 Boehringer Ingelheim International Gmbh Procédé de détermination d'une valeur de couleur future ou d'une propriété correspondante et agencement associé
WO2023151613A1 (fr) * 2022-02-10 2023-08-17 上海齐鲁制药研究中心有限公司 Molécule bispécifique de liaison à l'antigène et son utilisation
WO2023164474A1 (fr) 2022-02-23 2023-08-31 Amgen Inc. Traitement du cancer ciblant dll3
WO2023246885A1 (fr) * 2022-06-23 2023-12-28 江苏恒瑞医药股份有限公司 Molécule de liaison à l'antigène se liant spécifiquement à dll3 et cd3, et son utilisation pharmaceutique
WO2024089006A1 (fr) 2022-10-26 2024-05-02 Boehringer Ingelheim International Gmbh Composés hétérocycliques capables d'activer sting
WO2024089008A1 (fr) 2022-10-26 2024-05-02 Boehringer Ingelheim International Gmbh Composés hétérocycliques capables d'activer le sting
US20240166629A1 (en) 2022-10-26 2024-05-23 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
WO2024102693A2 (fr) 2022-11-07 2024-05-16 Xencor, Inc. Protéines de fusion il-18-fc

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1988001649A1 (fr) 1986-09-02 1988-03-10 Genex Corporation Molecules de liaison de chaines de polypeptide simples
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
GB9012995D0 (en) 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
EP0563214A4 (en) 1990-12-04 1994-08-17 Wistar Inst Bifunctional antibodies and method of preparing same
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
WO1993011161A1 (fr) 1991-11-25 1993-06-10 Enzon, Inc. Proteines multivalentes de fixation aux antigenes
PT1498427E (pt) 1992-08-21 2010-03-22 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
WO1995009917A1 (fr) 1993-10-07 1995-04-13 The Regents Of The University Of California Anticorps bispecifiques et tetravalents, obtenus par genie genetique
US5945311A (en) 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0739981A1 (fr) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
ATE218143T1 (de) 1996-09-03 2002-06-15 Gsf Forschungszentrum Umwelt Verwendung bi-und trispezifischer antikörper zur induktion einer tumorimmunität
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998050431A2 (fr) 1997-05-02 1998-11-12 Genentech, Inc. Procede de preparation d'anticorps multispecifiques presentant des composants heteromultimeres
MXPA01007170A (es) 1999-01-15 2002-07-30 Genentech Inc Variantes de polipeptidos con funcion efectora alterada.
US6649138B2 (en) 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
EP2357187A1 (fr) 2000-12-12 2011-08-17 MedImmune, LLC Molécules à demi-vies longues, compositions et utilisations de celles-ci
US20020083888A1 (en) 2000-12-28 2002-07-04 Zehnder Donald A. Flow synthesis of quantum dot nanocrystals
WO2003092043A2 (fr) 2001-07-20 2003-11-06 Quantum Dot Corporation Nanoparticules luminescentes et techniques de preparation
US20050100543A1 (en) 2003-07-01 2005-05-12 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
NZ563202A (en) 2005-07-15 2011-02-25 Nissan Chemical Ind Ltd Thiophene compounds and thrombopoietin receptor activators
AU2006301492B2 (en) * 2005-10-11 2011-06-09 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
HUE035250T2 (hu) 2005-10-12 2018-05-02 Morphosys Ag Humán CD38-ra specifikus teljesen humán HuCAL GOLD-eredetû terápiás ellenanyagok létrehozása és profilozása
EP1960552A2 (fr) 2005-12-16 2008-08-27 Genentech, Inc. Methode de diagnostic, de pronostic et de traitement du gliome
US20070274985A1 (en) 2006-05-26 2007-11-29 Stefan Dubel Antibody
PE20110218A1 (es) 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CN102448985B (zh) * 2009-05-27 2015-08-05 霍夫曼-拉罗奇有限公司 三或四特异性抗体
EP2975051B1 (fr) 2009-06-26 2021-04-14 Regeneron Pharmaceuticals, Inc. Anticorps bispécifiques facilement isolés avec un format natif d'immunoglobuline
WO2011028753A1 (fr) 2009-09-01 2011-03-10 Genentech, Inc. Purification améliorée d'une protéine grâce à une élution modifiée de la protéine a
CN109293768A (zh) 2009-12-23 2019-02-01 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 减少免疫原性的方法
HRP20211444T1 (hr) 2010-01-29 2021-12-24 Chugai Seiyaku Kabushiki Kaisha Anti-dll3 antitijelo
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
EP2576621B1 (fr) 2010-05-27 2019-04-10 Genmab A/S Anticorps monoclonaux contre her2
WO2012016227A2 (fr) 2010-07-29 2012-02-02 Xencor, Inc. Anticorps dont les points isoélectriques sont modifiés
WO2012106578A1 (fr) 2011-02-04 2012-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps neutralisant le vih, présentant des mutations dans le domaine constant (fc)
WO2012123949A1 (fr) 2011-03-17 2012-09-20 Ramot At Tel-Aviv University Ltd. Anticorps asymétriques bi- et monospécifiques et leur procédé de génération
CA2832387A1 (fr) 2011-04-20 2012-10-26 Genmab A/S Anticorps bispecifiques contre her2
WO2012143524A2 (fr) 2011-04-20 2012-10-26 Genmab A/S Anticorps bispécifiques contre her2 et cd3
KR20220114104A (ko) 2011-06-23 2022-08-17 아블린쓰 엔.브이. 면역글로불린 단일 가변 도메인을 수반하는 어세이에서 비특이적 단백질 간섭을 예측하고 검출하고 감소시키는 기법
CA2845029A1 (fr) 2011-08-17 2013-02-21 Glaxo Group Limited Proteines et peptides modifies
EP3418306B1 (fr) 2011-10-11 2023-12-06 F. Hoffmann-La Roche AG Ensemble amélioré d'anticorps bispécifiques
PT2771364T (pt) 2011-10-27 2019-09-10 Genmab As Produção de proteínas heterodiméricas
WO2013096291A2 (fr) 2011-12-20 2013-06-27 Medimmune, Llc Polypeptides modifiés pour des échafaudages d'anticorps bispécifiques
RU2014138474A (ru) 2012-02-24 2016-04-10 СтемСентРкс, Инк. Новые модуляторы и способы применения
PT2838918T (pt) 2012-04-20 2019-08-23 Merus Nv Métodos e meios para a produção de moléculas heterrodiméricas do tipo ig
US20140072581A1 (en) * 2012-07-23 2014-03-13 Zymeworks Inc. Immunoglobulin Constructs Comprising Selective Pairing of the Light and Heavy Chains
CN104955953B (zh) 2012-11-27 2019-04-26 亚洲大学校产学协力团 高效诱导抗体重链恒定区的异源二聚体形成的ch3域变体对，其制备方法及用途
GB201302447D0 (en) * 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
PL2992010T3 (pl) 2013-04-29 2021-08-23 F.Hoffmann-La Roche Ag Modyfikowane asymetryczne przeciwciała wiążące receptor Fc i sposoby ich stosowania
UA120753C2 (uk) * 2013-12-17 2020-02-10 Дженентек, Інк. Біспецифічне антитіло до сd3 та cd20
EP3140392B1 (fr) 2014-05-06 2023-07-26 F. Hoffmann-La Roche AG Production de protéines hétéromultimères au moyen de cellules mammaliennes
TW201609811A (zh) * 2014-07-31 2016-03-16 安美基研究（慕尼黑）公司 具有增強之組織分布之雙特異性單鏈抗體構築體
GB201414823D0 (en) 2014-08-20 2014-10-01 Argen X Bv Multispecific antibodies
WO2016036918A1 (fr) 2014-09-03 2016-03-10 Boehringer Ingelheim International Gmbh Composé ciblant il-23a et tnf-alpha, et ses utilisations
AR102522A1 (es) 2014-11-06 2017-03-08 Hoffmann La Roche Variantes de región fc con propiedades modificadas de unión a fcrn y proteína a
EP3317299A1 (fr) * 2015-06-30 2018-05-09 Boehringer Ingelheim International GmbH Protéines de liaison multi-spécifiques
TWI796283B (zh) * 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI793062B (zh) * 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
CN107921130A (zh) * 2015-08-17 2018-04-17 宏观基因有限公司 能够结合b7‑h3和cd3的双特异性单价双抗体及其用途
DK3458478T3 (da) 2016-05-18 2021-03-22 Boehringer Ingelheim Int Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling
BR112020020604A2 (pt) * 2018-04-11 2021-01-12 Inhibrx, Inc. Construções de polipeptídeo multiespecífico tendo ligação restrita de cd3 e métodos e usos relacionados
KR20200083879A (ko) 2018-12-31 2020-07-09 삼성디스플레이 주식회사 색변환 기판 및 표시 장치

Also Published As

Publication number Publication date
IL279235A (en) 2021-01-31
US20220251236A1 (en) 2022-08-11
BR112020022898A2 (pt) 2021-02-23
PE20210321A1 (es) 2021-02-16
CA3099956A1 (fr) 2019-12-12
PH12020552080A1 (en) 2021-05-31
ECSP20084864A (es) 2021-05-31
JP2021526816A (ja) 2021-10-11
US11332541B2 (en) 2022-05-17
JP7133043B2 (ja) 2022-09-07
EP3802598A1 (fr) 2021-04-14
AU2019280900A1 (en) 2020-11-19
CN112513092A (zh) 2021-03-16
CO2020015172A2 (es) 2020-12-21
SG11202011134XA (en) 2020-12-30
KR20210018311A (ko) 2021-02-17
US20230295337A1 (en) 2023-09-21
US20190375849A1 (en) 2019-12-12
CR20200601A (es) 2021-01-26
MX2020013348A (es) 2021-03-09
JOP20200313A1 (ar) 2020-12-06
JP2022180379A (ja) 2022-12-06
WO2019234220A1 (fr) 2019-12-12
TW202016151A (zh) 2020-05-01
CL2020003105A1 (es) 2021-06-11

Similar Documents

Publication Publication Date Title
MA52742A (fr) Anticorps bispécifiques dll3-cd3
MA53434A (fr) Anticorps anti-tigit
MA52884A (fr) Anticorps anti-il-11
MA50505A (fr) Anticorps 2 + 1 bispécifiques (contorsbodies)
MA47694A (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
MA47268A (fr) Anticorps anti-gpc3
MA46057A (fr) Anticorps anti-ctla4
MA45255A (fr) Anticorps inhibiteurs de points de contrôle bispécifiques
DK3455257T3 (da) Anti-pd-l1-antistoffer
MA42626A (fr) Nouveaux anticorps anti-pd-1
MA43028A (fr) Anticorps bispécifiques pour pd1 et tim3
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
MA53297A (fr) Anticorps anti-icos
MA46952A (fr) Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet
MA50352A (fr) Anticorps multispécifiques
MA52366A (fr) Anticorps anti-tl1a optimisés
DK3606961T3 (da) Garp-tgf-beta-antistoffer
MA49749A (fr) Anticorps anti-cd137
MA52212A (fr) Anticorps multivalent
DK3441086T3 (da) Monoklonalt anti-PD-1-antistof
MA44054A (fr) Plateforme d'anticorps bispécifique
MA40901A (fr) Anticorps bispécifiques anti-tnf/anti-il-3
MA52152A (fr) Anticorps
MA53905A (fr) Anticorps stabilisant trem2